Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584394 | 0.90 | CNR2 (0.43) | PDE4BCNR2TP53MAPTPDE4A | |
| SCHEMBL5584142 | 0.89 | PDE4B (0.44) | PDE4BCNR2TP53MAPTSRC | |
| SCHEMBL5584596 | 0.86 | PDE4B (0.41) | PDE4BCNR2TP53MAPTPDE4A | |
| SCHEMBL5584830 | 0.86 | MAPT (0.39) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL5584166 | 0.84 | CNR2 (0.45) | PDE4BCNR2TP53MAPTPDE4D | |
| SCHEMBL1925446 | 0.83 | CNR2 (0.49) | PDE4BCNR2MAPTPDE4APDE4C | |
| SCHEMBL5584513 | 0.80 | CNR2 (0.53) | PDE4BCNR2TP53MAPTPOLB | |
| SCHEMBL5584480 | 0.80 | ALDH1A1 (0.39) | PDE4BCNR2TP53MAPTPDE4A | |
| SCHEMBL5584809 | 0.80 | PDE4A (0.37) | PDE4BTP53MAPTPDE4APDE4C | |
| SCHEMBL5584459 | 0.80 | KMT2A (0.49) | PDE4BCNR2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211577-B2 | Water-soluble phenylpyridazine derivative and medicine containing the same | KOWA CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1604984-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | IL1B, IL1A, IL1R1 | PDE4B 2058/4885CNR2 2914/4885TP53 1443/4885 |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | PDE4B 3545/4885CNR2 1362/4885TP53 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.